Efficacy of 7-valent pneumococcal conjugate vaccination in Germany: An analysis using the indirect cohort method

Vaccine. 2010 Jul 12;28(31):5012-6. doi: 10.1016/j.vaccine.2010.05.021. Epub 2010 May 21.

Abstract

Efficacy of 7-valent pneumococcal conjugate vaccination has been shown in randomized controlled trials using 4 dose vaccination schedules in children under 2 years of age. A case-control study from the US showed considerable protection from IPD for reduced vaccination schedules and even some protection from only one dose. In Germany, delayed and incomplete vaccination is a major issue. We assessed efficacy of PCV7 using data on cases of IPD from active surveillance and applying the indirect cohort design proposed by Broome, comparing cases of IPD with a vaccine serotype with cases with a non-vaccine serotype. Efficacy of at least one dose of PCV7 was estimated to be 88.3% (95% CI: 64.0-96.6). Estimates of efficacy for one, two, and three doses in the first 7 months of life were 78.1% (3.4-96.1), 89.8% (20.6-100.0), and 94.6% (69.7-99.5) respectively. Our study adds to evidence of good protection from IPD by reduced vaccination schedules with PCV7, e.g. with two doses as primary series, in a setting where a high proportion of children receives vaccination delayed.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Child, Preschool
  • Female
  • Germany / epidemiology
  • Heptavalent Pneumococcal Conjugate Vaccine
  • Humans
  • Immunization Schedule*
  • Infant
  • Male
  • Pneumococcal Infections / epidemiology
  • Pneumococcal Infections / immunology
  • Pneumococcal Infections / prevention & control*
  • Pneumococcal Vaccines / immunology*
  • Population Surveillance
  • Prospective Studies
  • Vaccines, Conjugate / immunology

Substances

  • Heptavalent Pneumococcal Conjugate Vaccine
  • Pneumococcal Vaccines
  • Vaccines, Conjugate